CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE

Size: px
Start display at page:

Download "CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE"

Transcription

1 ESC Congress Aug - 31 Aug 2011, Paris - France CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE N.Russo, L.Compostella, T.Setzu, M.Napodano, L.Testolin, G.Isabella, G.Gerosa, S.Iliceto, F.Bellotto Preventive Cardiology and Rehabilitation, Istituto Codivilla Putti di Cortina d Ampezzo Dpt of Cardiac, Thoracic and Vascular Sciences, Padua University Medical School Conflicts of interest, sources of support and funding disclosure: none

2 Aortic Stenosis Ross J, Braunwald E. Circulation 1968;38:61-67 and Ross J Jr. JACC 2008;51:

3 Survival in elderly patients with severe aortic stenosis is dramatically improved by aortic valve replacement Varadarajan P et al. Euro J Cardiothorac Surg 2006; 30:

4

5 Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery Leon MB, Smith CR, et al. NEJM 2010; 363:

6 Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients Smith CR, Leon MB, et al. NEJM 2011; 364:

7 CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE Cardiac Rehabilitation (CR) is a well-established treatment in patients who underwent cardiac surgery. Beneficial effects on exercise capacity, quality of life and reduction of recurrent events and hospitalization are reported in various studies using different programs. After Transcatheter Aortic Valve Implantation (TAVI), older patients with more compromised conditions are natural candidates for referral to in-hopital CR programs No data are available, until now, about the safety, efficacy and duration of cardiac rehabilitation in these subjects.

8 CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE A prospective single centre study (July 2008-April 2011) to evaluate safety and efficacy of early cardiac rehabilitation in elderly patients (>75 y) who underwent TAVI CoreValve=15 Edwards AP=11 45 TAVI 48 savr (as control) Mean age: 82.1 ± 3.6 Edwards TF=19 TAVI=TRANSCATHETER AORTIC VALVE IMPLANTATION savr = SURGICAL AORTIC VALVE REPLACEMENT AP= transapical approach TF=transfemoral approach

9 CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE Clinical features (1) TAVI savr ALL p n=45 n=48 n=93 Age (y) 83.3± ± ± Age [min-max] [77-89] [76-88] [76-89] Male (%) Time impl-rehab (days) 13.3± ± ± Stay in CR (days) 16.6± ± ± Drop out (n/tot) (%) 1/45 (2.2%) 1/48 (2.0%) 2/90 (2.2%) 0.89 Causes Arrhythmias Acute Abdomen

10 CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE Clinical features (2) TAVI (n=45) savr (n=48) ALL (n=93) p Hypertension (%) Diabetes (%) Pre-diabetes (%) Met Synd (%) Coronary art dis (%) Prev MI (%) Prev PCI (%) <0.01 Prev CABG (%) Vascular disease (%) Pulmonary disease (%) Renal Failure (%) Cancer (%)

11 CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE Clinical features (3) TAVI (n=45) savr (n=48) ALL (n=93) p New Pace Maker (%) Atrial fibrillation (%) LBBB (%) <0.01 BMI (kg/m 2 ) 24.7± ± ± Hb value at entry (g/dl) 10.3± ± ± LVEF (%) 56.3± ± ± NYHA 2.93± ± ±

12 CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE Exercise based Cardiac Rehabilitation 3 sets of exercises, 6 days a week each session supervised by a physician and a physiotherapist

13 CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE Barthel Index TAVI savr ALL p At entry B.I. 80.9± ± ± At discharge B.I. 90.3± ± ± Δ B.I. 9.3± ± ± At the end of the CR period, all patients enhanced independence and mobility and were able to walk al least with the assistance of a stick

14 CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE 6MWT 289 ± 99 savr (n = 42) 266 ± ± 97 TAVI (n = 31) 238 ± 95 mean Δ6MWT: + 66±54 P<0.01

15 CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE CPET peak VO 2 (ml/kg/min) p=0.13 savr (n = 31) TAVI (n = 17)

16 CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE Functional status TAVI savr ALL p 6MWT (n/tot) (%) 31/45 (69%) 42/48 (88%) 73/93 (78%) At entry (mt) 237.8± ± ± Pre-discharge (mt) 266.6± ± ± Δ6MWT (mt) 58.0± ± ± CPET (n/tot) (%) 17/45 (38%) 31/48 (65%) 48/93 (52%) Peak VO2 (ml/kg/min) 12.2± ± ±

17 CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE Conclusions In elderly patients after TAVI, intensive, exercised based CR is feasible, safe and effective as after traditional cardiac surgery In our experience, the length of the hospital stay was relatively brief, despite the older age and the number of comorbidities of the patients enrolled Intensive CR should be encouraged in TAVI patients in order to optimize functional recovery and reduce the length of stay in acute care divisions

18 CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE Limitations This is an observational clinical study and not a randomized trial These preliminary data need to be extended

19 Grazie dell attenzione.. Thank You

TAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:

TAVR in patients with. End-Stage CKD or in Renal Replacement Therapy: TAVR in patients with End-Stage CKD or in Renal Replacement Therapy: Special Considerations and Prevention of early Valve Failure Antonios Chalapas, MD, PhD, FESC THV & Hygeia Hospital Heart Team Athens,

More information

Aortic valve implantation using the femoral and apical access: a single center experience.

Aortic valve implantation using the femoral and apical access: a single center experience. Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany

More information

Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?

Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional

More information

TAVI After PARTNER-2 : The Hamilton Approach

TAVI After PARTNER-2 : The Hamilton Approach TAVI After PARTNER-2 : The Hamilton Approach James L. Velianou MD FRCPC Interventional Cardiology Hamilton General Hospital St Catharines General Hospital Associate Professor of Medicine McMaster University

More information

Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients:

Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 1-Year Results from the SURTAVI Clinical Trial Nicolas M. Van

More information

Appropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement in The PARTNER I Trial Wilson Y.

Appropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement in The PARTNER I Trial Wilson Y. Appropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement in The PARTNER I Trial Wilson Y. Szeto, MD on behalf of The PARTNER Trial Investigators and The PARTNER

More information

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection

More information

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo

More information

Strokes After TAVR Reasons for Declining Frequency

Strokes After TAVR Reasons for Declining Frequency Strokes After TAVR Reasons for Declining Frequency Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory Cleveland Clinic Disclosure NONE Second Generation Valves Newer

More information

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular

More information

Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute

Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries

More information

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More? CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology

More information

Percutaneous Management of Severe AS in Octagenarians. Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington

Percutaneous Management of Severe AS in Octagenarians. Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington Percutaneous Management of Severe AS in Octagenarians Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington May 2017 Outline Aetiology of AS Natural History of AS Assessment

More information

Aortic Stenosis in the Elderly: Difficulties for the Clinician. Are Symptoms Due to Aortic Stenosis?

Aortic Stenosis in the Elderly: Difficulties for the Clinician. Are Symptoms Due to Aortic Stenosis? Aortic Stenosis in the Elderly: Difficulties for the Clinician Are Symptoms Due to Aortic Stenosis? Raphael Rosenhek Department of Cardiology Medical University of Vienna No disclosure European Society

More information

Prof. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation

Prof. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation Prof. Dr. Thomas Walther TAVI in ascending aorta / aortic root dilatation nn AorticStenosis - Guidelines TAVI and aortic aneurysm? Few data published. EJCTS 2014;46:228-33 TAVI and aortic aneurysm? Few

More information

RANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING

RANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING AORTIC VALVE DISEASE RANDOMISED TRIALS COMPARING TAVI WITH SAVR STEPHAN WINDECKER DEPARTMENT OF CARDIOLOGY SWISS CARDIOVASCULAR CENTER AND CLINICAL TRIALS UNIT BERN BERN UNIVERSITY HOSPITAL, SWITZERLAND

More information

Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France

Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France Faculty disclosure Bernard Iung I disclose the following financial relationships: Consultant

More information

Establishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS

Establishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS Establishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T h e Pa

More information

LOW RISK TAVR. WHAT THE FUTURE HOLDS

LOW RISK TAVR. WHAT THE FUTURE HOLDS LOW RISK TAVR. WHAT THE FUTURE HOLDS Michael J. Reardon, M.D. Professor of Cardiothoracic Surgery Allison Family Distinguish Chair of Cardiovascular Research Houston Methodist DeBakey Heart & Vascular

More information

Post-TAVI Cerebral Embolisms and Potential Protection Means

Post-TAVI Cerebral Embolisms and Potential Protection Means Post-TAVI Cerebral Embolisms and Potential Protection Means Josep Rodés-Cabau, MD Quebec Heart & Lung Institute, Laval University Quebec City, Quebec, Canada EBR Marseille, May 2012 Conflict of Interest

More information

Strokes After TAVR. Ioannis Iakovou, MD, PhD. Interventional Cardiology Onassis Cardiac Surgery Center

Strokes After TAVR. Ioannis Iakovou, MD, PhD. Interventional Cardiology Onassis Cardiac Surgery Center Strokes After TAVR Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Strokes After TAVR How common is stroke after TAVR Is it increasing? Is it more with TF vs TA? Is it

More information

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant

More information

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine

More information

TAVI: Nouveaux Horizons

TAVI: Nouveaux Horizons TAVI: Nouveaux Horizons EUAPI580i 432HQ14NP02353 Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Objectifs Les recommandations Le TAVI en chiffre La

More information

Prospective Evaluation of the Eyeball Test for Assessing Frailty in Elderly Patients with Valvular Heart Disease

Prospective Evaluation of the Eyeball Test for Assessing Frailty in Elderly Patients with Valvular Heart Disease Prospective Evaluation of the Eyeball Test for Assessing Frailty in Elderly Patients with Valvular Heart Disease Background Frailty is a common occurrence in elderly patients Approximately half of the

More information

EuroScore II and STS score: are they similar? Julien Magne, PhD CHU Limoges, France

EuroScore II and STS score: are they similar? Julien Magne, PhD CHU Limoges, France EuroScore II and STS score: are they similar? Julien Magne, PhD CHU Limoges, France Faculty disclosure Julien Magne I have no financial relationships to disclose. Discrimination vs. Calibration The best

More information

Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea

Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea Contents Decision making in surgical AVR in old age Clinical results of AVR with tissue valve Impact of 19mm

More information

The Role of TAVI in high-risk and normal-risk Patients

The Role of TAVI in high-risk and normal-risk Patients The Role of TAVI in high-risk and normal-risk Patients Joachim Schofer Hamburg University Cardiovascular Center and Department for percutaneous treatment of structural heart disease Albertinen Heart Center

More information

Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter

Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter Nirat Beohar, MD Associate Professor of Medicine Director Cardiac Catheterization Laboratory, Medical Director Structural

More information

TAVR for Valve-In-Valve. Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology

TAVR for Valve-In-Valve. Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology TAVR for Valve-In-Valve Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology Temple Hearth and Vascular Institute Disclosures: Consultant: Cardiac Assist TAVR for

More information

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation Susheel Kodali, MD Director, Structural Heart & Valve

More information

For the SURTAVI Investigators

For the SURTAVI Investigators Neurological complications after transcatheter aortic valve implantation with a self-expanding bioprosthesis or surgical aortic valve replacement in patients at intermediate-risk for surgery A. Pieter

More information

Transcatheter Aortic Valve Replacement

Transcatheter Aortic Valve Replacement Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis

More information

Transcatheter Valve Replacement: Current State in 2017

Transcatheter Valve Replacement: Current State in 2017 Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP

More information

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40 Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human

More information

Is Stroke Frequency Declining?

Is Stroke Frequency Declining? Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac

More information

Incidence And Predictors Of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation

Incidence And Predictors Of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation Incidence And Predictors Of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation Ömer Aktug 1, MD; Guido Dohmen 2, MD; Kathrin Brehmer 1, MD; Verena Deserno 1 ; Ralf Herpertz 1 ; Rüdiger

More information

TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre

TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre Disclosure St. Jude Medical: Consultant and Proctor Edwards Lifesciences: Proctor Medtronic: Research

More information

Alex versus Xience Registry Preliminary report

Alex versus Xience Registry Preliminary report Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor

More information

How to Prevent Thromboembolic Complications in TAVI

How to Prevent Thromboembolic Complications in TAVI How to Prevent Thromboembolic Complications in TAVI PETER WENAWESER, MD Swiss Cardiovascular Centre, University Hospital, Bern, Switzerland Potential Conflicts of Interest Proctoring and lecture fees from

More information

Cardiac Rehabilitation for Heart Failure Patients. Jia Shen MD, MPH Assistant Professor of Medicine UC San Diego Health System

Cardiac Rehabilitation for Heart Failure Patients. Jia Shen MD, MPH Assistant Professor of Medicine UC San Diego Health System Cardiac Rehabilitation for Heart Failure Patients Jia Shen MD, MPH Assistant Professor of Medicine UC San Diego Health System Disclosures There are no conflict of interests related to this presentation.

More information

TAVR y Enfermedad Coronaria. Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Associate Professor of Medicine

TAVR y Enfermedad Coronaria. Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Associate Professor of Medicine TAVR y Enfermedad Coronaria Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Associate Professor of Medicine CAD and AS Similar Pathological Processes CAD in TAVR Patients (n=390)

More information

Indication, Timing, Assessment and Update on TAVI

Indication, Timing, Assessment and Update on TAVI Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical

More information

When Should We Consider TAVI. (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea

When Should We Consider TAVI. (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea When Should We Consider TAVI Procedure in Korea (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea Aortic Stenosis in Korea Rapidly increasing valve disease in Korea Still low incidence

More information

Cardiac Rehabilitation & Exercise Training in Congenital Heart Disease. Jidong Sung Division of Cardiology Sungkyunkwan University School of Medicine

Cardiac Rehabilitation & Exercise Training in Congenital Heart Disease. Jidong Sung Division of Cardiology Sungkyunkwan University School of Medicine Cardiac Rehabilitation & Exercise Training in Congenital Heart Disease Jidong Sung Division of Cardiology Sungkyunkwan University School of Medicine Cardiac rehabilitation Agency of Health Care Policy

More information

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age

More information

TAVR for low-risk patients in 2017: not so fast.

TAVR for low-risk patients in 2017: not so fast. TAVR for low-risk patients in 2017: not so fast. Enrico Ferrari, MD, FETCS Cardiac Surgery Department Cardiocentro Ticino Foundation Lugano, Switzerland Conflicts of Interest Consultant and proctor for

More information

Disclosures. LGH TAVR: Presentation Outline 2/2/2016. Updates in Transcatheter Aortic Valve Replacement (TAVR) and the LGH Experience

Disclosures. LGH TAVR: Presentation Outline 2/2/2016. Updates in Transcatheter Aortic Valve Replacement (TAVR) and the LGH Experience Updates in Transcatheter Aortic Valve Replacement (TAVR) and the LGH Experience The LGH TAVR Program James E. Harvey, MD, MSc Medical Director, Structural Heart Intervention The Heart Group of Lancaster

More information

Percutaneous Aortic Valvuloplasty: Long-Term Survival

Percutaneous Aortic Valvuloplasty: Long-Term Survival Percutaneous Aortic Valvuloplasty: Long-Term Survival Angioplasty Summit Seoul April 27, 2007 James R. Margolis MD Carmen Paez MD, Kevin Coy MD, Edward Freeman PhD Miami International Cardiology Consultants

More information

Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update

Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Howard J Broder MD Interventional Cardiology DaVita Medical Group/ Healthcare Partners Cardiology Disclosures for Howard J Broder

More information

Vinod H. Thourani, MD, FACC, FACS

Vinod H. Thourani, MD, FACC, FACS Considering SAVR in the TAVR era: Surgical Implications of TAVR Vinod H. Thourani, MD, FACC, FACS Professor of Cardiothoracic Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown

More information

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France Future Percutaneous Therapies for Mitral Valve Disease (Mitraclip,percutaneous annuloplasty and transcatheter valve implantation) Will they reach the TAVI s success? Alec Vahanian,FESC, FRCP (Edin.) Bichat

More information

Appropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK

Appropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK Appropriate Use of TAVR - now and in the future A Surgeon s Perspective Neil Moat Royal Brompton Hospital, London, UK Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner

More information

Exercise after CABG: The Good The Bad and the Ugly

Exercise after CABG: The Good The Bad and the Ugly Exercise after CABG: The Good The Bad and the Ugly Ph Meurin. Les Grands Prés (Villeneuve Saint Denis) No conflict of Interest After CABG, the Prognosis is Good.. Age 65 ± 10 Male Gender 80 % Pre-op LVEF

More information

Aortic Stenosis: Background

Aortic Stenosis: Background Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic

More information

The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD

The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New

More information

Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia

Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia Transcatheter Transapical Aortic Valve Implantation Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia Ahmed Elwatidy, MD,PhD, FRCS S Kassab, MD,S Ahmari, MD, H Amri, MD, H Ismail, MD, A Calafiori,

More information

L evoluzione nel management della valvulopatia aortica

L evoluzione nel management della valvulopatia aortica L evoluzione nel management della valvulopatia aortica Giuseppe Tarantini, MD, PhD, FESC Director of Interventional Cardiology University of Padua GISE president TAVI: BIG BANG 2002 TAVI - EVOLUTIONs Commitment

More information

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III On Behalf of the CoreValve US Clinical Investigators

More information

22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2.

22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2. Oxford City Transcatheter aortic valve replacement 2017 guidelines Monday 19 th June Jim Newton Oxford Oxford University Hospitals NHS FT How familiar are you with TAVR? 1. First time I have heard about

More information

Bernard De Bruyne, MD, PhD Cardiovascular Center Aalst OLV-Clinic Aalst, Belgium

Bernard De Bruyne, MD, PhD Cardiovascular Center Aalst OLV-Clinic Aalst, Belgium Medium Term Survival and Functional Status in Patients with Severe Aortic Stenosis Treated by Transcatheter Aortic Valvular Implantation in the PARTNER EU Trial Bernard De Bruyne, MD, PhD Cardiovascular

More information

Rapid deployment aortic valve replacement for the treatment of severe aortic stenosis in high risk patients. Β. Κόλλιας, Σ. Ματιάτου, Δ. Αγγουράς.

Rapid deployment aortic valve replacement for the treatment of severe aortic stenosis in high risk patients. Β. Κόλλιας, Σ. Ματιάτου, Δ. Αγγουράς. Rapid deployment aortic valve replacement for the treatment of severe aortic stenosis in high risk patients. Οι βιοπροσθετικές αορτικές βαλβίδες ταχείας έκπτυξης στην αντιµετώπιση της σοβαρής αορτικής

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter

More information

Cardiac rehabilitation: a beneficial effect in CHD?

Cardiac rehabilitation: a beneficial effect in CHD? Cardiac rehabilitation: a beneficial effect in CHD? An Van Berendoncks Department of Cardiology Antwerp University Hospital Outline Why exercise training in CHD? Risk and benefits? Feasibility? Why should

More information

Variability in Antithrombotic Therapy Regimens Peri-TAVR: A Single Academic Center Experience

Variability in Antithrombotic Therapy Regimens Peri-TAVR: A Single Academic Center Experience DOI 10.1007/s40119-015-0050-2 BRIEF REPORT Variability in Antithrombotic Therapy Regimens Peri-TAVR: A Single Academic Center Experience Jeffrey E. Rossi. Andrew Noll. Brian Bergmark. James M. McCabe.

More information

Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know

Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts

More information

Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?

Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval? Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval? Update from PARTNER EU and SOURCE Registries T. Lefèvre Disclosure Statement Cardiologist Interventional cardiologist 1 st PABV in

More information

Quality Measures MIPS CV Specific

Quality Measures MIPS CV Specific Quality Measures MIPS CV Specific MEASURE NAME Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy CAHPS for MIPS Clinician/Group Survey Cardiac Rehabilitation Patient Referral from

More information

Emergency TAVI: Does It Exist? Is the Risk Higher?

Emergency TAVI: Does It Exist? Is the Risk Higher? Emergency TAVI: Does It Exist? Is the Risk Higher? Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia APCASH 12 October 2014 Disclosure Statement of

More information

Clinical Considerations of High Intensity Interval Training (HIIT)

Clinical Considerations of High Intensity Interval Training (HIIT) Clinical Considerations of High Intensity Interval Training (HIIT) Jenna Taylor Exercise Physiologist & Dietitian The Wesley Hospital PhD Candidate The University of Queensland What is High Intensity Interval

More information

Risk Patients Before TAVI or AVR

Risk Patients Before TAVI or AVR Balloon Aortic Valvuloplasty for Highest Risk Patients Before TAVI or AVR Dariusz Dudek Chair of the Board of the Institute of Cardiology Jagiellonian University, Kraków, Poland Chair, Education & Training

More information

Policy Specific Section: March 30, 2012 March 7, 2013

Policy Specific Section: March 30, 2012 March 7, 2013 Medical Policy Transcatheter Aortic Valve Replacement for Aortic Stenosis Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective Date:

More information

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000

More information

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital

More information

Saudi Heart Association. Raising Standards through Education and Training

Saudi Heart Association. Raising Standards through Education and Training Saudi Heart Association Raising Standards through Education and Training 25th Annual Meeting EACTS Lisbon, Oc ctober 2011 WWW EA WWW. ACTS ORG ACTS.ORG Clinical decision making in case of Aortic valve

More information

Preliminary Programme

Preliminary Programme Preliminary Programme The scientific programme comprises various styles of presentations and sessions, each offering a unique opportunity to amass new and important scientific information. Optimal management

More information

TAVR IN INTERMEDIATE-RISK PATIENTS

TAVR IN INTERMEDIATE-RISK PATIENTS TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS

More information

Dysfunction of transcatheter mitral valve prosthesis. Early valve degeneration or thrombosis - that is the question.

Dysfunction of transcatheter mitral valve prosthesis. Early valve degeneration or thrombosis - that is the question. Dysfunction of transcatheter mitral valve prosthesis. Early valve degeneration or thrombosis - that is the question. Böhm A., Hricak V., Tomasovic B., Bena M., Postulka J. The National Institute of, Department

More information

Transcatheter aortic valve implantation and pre-procedural risk assesment

Transcatheter aortic valve implantation and pre-procedural risk assesment Transcatheter aortic valve implantation and pre-procedural risk assesment Alec Vahanian,FESC, FRCP(Edin.) Bichat Hospital University Paris VII, Paris, France Disclosures Relationship with companies who

More information

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect

More information

The importance of follow-up after a cardiac event: CARDIAC REHABILITATION. Dr. Guy Letcher

The importance of follow-up after a cardiac event: CARDIAC REHABILITATION. Dr. Guy Letcher The importance of follow-up after a cardiac event: CARDIAC REHABILITATION Dr. Guy Letcher The National Medicare Experience Mortality After Angioplasty 225,915 patients Mortality After Bypass Surgery 357,885

More information

UC Merced UC Merced Undergraduate Research Journal

UC Merced UC Merced Undergraduate Research Journal UC Merced UC Merced Undergraduate Research Journal Title TAVI: A Safe Alternative for Aortic Stenosis? Permalink https://escholarship.org/uc/item/5d01f0p3 Journal UC Merced Undergraduate Research Journal,

More information

Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry

Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry E Van Belle, E Teiger, F Juthier, A Vincentelli, B Iung, H Eltchaninoff, J Fajadet,

More information

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division

More information

BACPR Annual Conference Generic versus Specialist Rehabilitation FOR

BACPR Annual Conference Generic versus Specialist Rehabilitation FOR BACPR Annual Conference 2016 Generic versus Specialist Rehabilitation FOR Dr William Man 1) Organ-specific rehabilitation for heart failure and COPD is an outdated concept... 2) Rehabilitation should

More information

J. Schwitter, MD, FESC Section of Cardiology

J. Schwitter, MD, FESC Section of Cardiology J. Schwitter, MD, FESC Section of Cardiology CMR Center of the CHUV University Hospital Lausanne - CHUV Switzerland Centre de RM Cardiaque J. Schwitter, MD, FESC Section of Cardiology CMR Center of the

More information

Valvular Intervention

Valvular Intervention Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone

More information

2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR

2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of

More information

Incidence and Management of Early Implant Failure after Transcatheter Aortic Valve Implantation

Incidence and Management of Early Implant Failure after Transcatheter Aortic Valve Implantation ESC Congress 2010 28 Aug 2010-01 Sep 2010 Stockholm - Sweden Incidence and Management of Early Implant Failure after Transcatheter Aortic Valve Implantation Gian Paolo Ussia, MD Director of Interventional

More information

Aortic Stenosis: Open vs TAVR vs Nothing

Aortic Stenosis: Open vs TAVR vs Nothing Aortic Stenosis: Open vs TAVR vs Nothing Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division

More information

Are Heart Valve Referral Centers Feasible in Latin America?

Are Heart Valve Referral Centers Feasible in Latin America? Are Heart Valve Referral Centers Feasible in Latin America? Vadim Kotowicz, MD Chief of Cardiovascular Surgery Department Italian Hospital of Buenos Aires Disclosure Medtronic inc. Consultanting Johnson

More information

Ischemic Ventricular Septal Rupture

Ischemic Ventricular Septal Rupture Ischemic Ventricular Septal Rupture Optimal Management Strategies Juan P. Umaña, M.D. Chief Medical Officer FCI Institute of Cardiology Disclosures Abbott Mitraclip Royalties Johnson & Johnson Proctor

More information

The correlation of AVA measured by transthoracic, transesophageal echocardiography and cardiac CT

The correlation of AVA measured by transthoracic, transesophageal echocardiography and cardiac CT The correlation of AVA measured by transthoracic, transesophageal echocardiography and cardiac CT R.Petr, H.Linkova, J.Knot, E.Paskova, J.Daniel, M.Labos Cardiocenter of University Hospital Kralovske Vinohrady

More information

The Role of Exercise in Management of Patients with Heart Failure

The Role of Exercise in Management of Patients with Heart Failure The Role of Exercise in Management of Patients with Heart Failure Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Leadership Council and Section Director,

More information

Le TAVI pour tout le monde?

Le TAVI pour tout le monde? Le TAVI pour tout le monde? Thierry Lefèvre Institut Cardiovasculaire Paris Sud, Massy Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation or

More information

Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update

Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update T. Lefèvre Natural History of Aortic Stenosois 100 Latent period Survival (%) 80 60 40 20 Symptoms Average Age Death 0 40 50

More information

Severe Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative

Severe Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative Severe Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative Samin K. Sharma, MD, FACC, FSCAI Director Clinical & Interventional

More information

Edwards' solution for patients suffering from tricuspid valve disease

Edwards' solution for patients suffering from tricuspid valve disease Edwards' solution for patients suffering from tricuspid valve disease R. S. von Bardeleben, MD Head Structural and Heart Valve Center Heart Center Cardiology I, University Medicine Mainz Germany Potential

More information